Back to search

Peptide record

TPDB42666

P18-1 Anticancer standard
7 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42666
P18-1
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 7-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Cyclized Chemical: Substitution of hydroxyl group at Tyrosine with sulfonyl fluoride N-terminal: Cyclized
Sequence
PIPYPIF
Physicochemical Analysis
C45H63N7O9
ARNDCEQGHLKMSTWV
P
846.04
5.94
0
0
4
-0
-1.34
0.814
111.43
Mammalian: >20 hour Yeast: >20 hour E.coli: ?
1490
176.12
1
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
2
I
0
L
0
K
0
M
1
F
3
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 0 K: 0 M: 0 F: 1 P: 3 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
7
C45H63N7O9
846.04
5.94
-0
-1.34
0.814
Cyclized
Substitution of hydroxyl group at Tyrosine with sulfonyl fluoride
L
Cyclic
Cyclized
Anticancer
Analogue of Phakellistatin 18
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 = 67.53 µM
Anticancer
67.53 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

Cytotoxicity assay
Not Available

Source & Reference

CancerPPD 2.0
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 41.28 µM
Anticancer
41.28 µM

Target

Cervical Cancer
BEL-7042
Cervix

Assay & Model

Cytotoxicity assay
Not Available

Source & Reference

CancerPPD 2.0
CancerPPD2
2018